Letter to the Editor: Salidroside in ulcerative colitis - neuroimmune regulatory mechanisms and clinical translation prospects

Key Takeaways for GI Nurses

• Salidroside, a natural bioactive compound, is being investigated as an adjunct or alternative therapeutic approach for ulcerative colitis (UC), targeting the cAMP-PKA-CREB signaling pathway to reduce intestinal inflammation and support mucosal barrier repair.
• This research highlights a novel mechanism—regulation of enteric glial cells (EGCs) within the gut's neuro-glial-immune network—as a therapeutic target, expanding our understanding of UC pathophysiology beyond traditional immune-focused models.
• Current first-line UC therapies (5-ASA, corticosteroids, immunosuppressants) carry significant limitations including steroid dependence, infection risk, and drug resistance, underscoring the clinical need for new treatment options that nurses may encounter in future practice.
• While still in early-stage research, this emerging science reinforces the importance of patient education regarding the complex, multi-system nature of UC and may inform future conversations about complementary or integrative treatment approaches.

Clinical Relevance

For GI and endoscopy nurses managing patients with ulcerative colitis, understanding emerging research on novel therapeutic mechanisms is increasingly important as patients often ask about alternative or complementary treatments, particularly when conventional therapies fail to maintain remission or cause bothersome side effects. This letter to the editor discusses how salidroside may work through a previously underappreciated pathway—the enteric neuro-glial-immune network—suggesting that UC pathogenesis involves more than just immune dysregulation. Enteric glial cells, which nurses may not typically discuss with patients, appear to play a pathological role in perpetuating intestinal inflammation, and their modulation represents a new frontier in IBD therapeutics.

From a practical standpoint, this research does not yet translate into bedside protocol changes, but it does have implications for patient counseling and professional development. Nurses are often the first point of contact when patients inquire about "natural" or plant-derived therapies they've read about online, including compounds like salidroside (derived from Rhodiola rosea). Being able to accurately contextualize such research—explaining that preclinical and early mechanistic studies are promising but not yet equivalent to established clinical therapies—helps nurses provide evidence-based reassurance while avoiding both dismissiveness and overpromising. This is particularly relevant in endoscopy units where nurses frequently field questions during pre-procedure consultations or post-colonoscopy discussions about disease management.

Additionally, this research reinforces the broader clinical reality that UC management often requires looking beyond standard anti-inflammatory pathways. As IBD treatment continues to evolve toward personalized and multi-targeted approaches, GI nurses who stay informed about emerging mechanisms—such as neuro-immune crosstalk—will be better equipped to support multidisciplinary care teams, participate in patient education initiatives, and recognize when patients may benefit from referral to specialized IBD programs or clinical trials exploring novel agents.

Bottom Line

While salidroside remains an investigational compound rather than a clinically available treatment, this research signals a shifting understanding of UC pathogenesis that incorporates enteric glial cell activity and neuro-immune regulation—knowledge that can help GI nurses engage more confidently with patients curious about emerging therapies and contribute meaningfully to conversations about the evolving landscape of IBD care.